All In Biotech

Drug Trial Radar · NCT07253142

A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer

A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Combination With Serplulimab (Humanized Anti-PD-1 Monoclonal Antibody Injection) in Advanced Stage Lung Cancer

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Feb 5, 2026

Primary completion

Jun 18, 2027

Study completion Jun 19, 2028

Sponsor

Lead sponsor
Shanghai Henlius BiotechIndustry
Sponsor type
Industry
First posted
Nov 28, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is to explore the the reasonable dosage and to evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in combination with Serplulimab (anti-PD-1 humanized monoclonal antibody injection) in patients with advanced lung cancer.

Conditions

  • Non Small Cell Lung Cancer
  • Small Cell Lung Cancer

Interventions

  • HLX43 dose 1Drug

    HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.

  • HLX43 dose 2Drug

    HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ORRTime frame: up to 24 week

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • THE Affiliated Hospital of Xuzhou Medical University

    Xuzhou, China

  • The Second Hospital of Anhui Medical University

    Hefei, Anhui, China

  • Fujian Cancer Hospital

    Fu'zhou, Fujian, China

  • Cancer Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, China

  • The People's Hospital of Guangxi Zhuangzu Autonomous Region

    Nanning, Guangxi, China

  • Cangzhou People's Hospital

    Cangzhou, Hebei, China

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China

  • The First Affiliated Hospital of Xinxiang Medical University

    Xinxiang, Henan, China

  • Hubei Cancer Hospital

    Wuha, Hubei, China

  • Shanghai Chest Hospital

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.